» Articles » PMID: 16532490

Dysfunction of Endocytic and Autophagic Pathways in a Lysosomal Storage Disease

Overview
Journal Ann Neurol
Specialty Neurology
Date 2006 Mar 15
PMID 16532490
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To understand the mechanisms of skeletal muscle destruction and resistance to enzyme replacement therapy in Pompe disease, a deficiency of lysosomal acid alpha-glucosidase (GAA), in which glycogen accumulates in lysosomes primarily in cardiac and skeletal muscles.

Methods: We have analyzed compartments of the lysosomal degradative pathway in GAA-deficient myoblasts and single type I and type II muscle fibers isolated from wild-type, untreated, and enzyme replacement therapy-treated GAA knock-out mice.

Results: Studies in myoblasts from GAA knock-out mice showed a dramatic expansion of vesicles of the endocytic/autophagic pathways, decreased vesicular movement in overcrowded cells, and an acidification defect in a subset of late endosomes/lysosomes. Analysis by confocal microscopy of isolated muscle fibers demonstrated that the consequences of the lysosomal glycogen accumulation are strikingly different in type I and II muscle fibers. Only type II fibers, which are the most resistant to therapy, contain large regions of autophagic buildup that span the entire length of the fibers.

Interpretation: The vastly increased autophagic buildup may be responsible for skeletal muscle damage and prevent efficient trafficking of replacement enzyme to lysosomes.

Citing Articles

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.

Byrne B, Parenti G, Schoser B, van der Ploeg A, Do H, Fox B Front Neurol. 2024; 15():1451512.

PMID: 39494167 PMC: 11527667. DOI: 10.3389/fneur.2024.1451512.


An expert rule-based approach for identifying infantile-onset Pompe disease patients using retrospective electronic health records.

Rustamov J, Rustamov Z, Mohamad M, Zaki N, Al Tenaiji A, Al Harbi M Sci Rep. 2024; 14(1):21523.

PMID: 39277702 PMC: 11401873. DOI: 10.1038/s41598-024-72259-5.


Key considerations for investigating and interpreting autophagy in skeletal muscle.

Rahman F, Baechler B, Quadrilatero J Autophagy. 2024; 20(10):2121-2132.

PMID: 39007805 PMC: 11423691. DOI: 10.1080/15548627.2024.2373676.


Failure of Autophagy in Pompe Disease.

Do H, Meena N, Raben N Biomolecules. 2024; 14(5).

PMID: 38785980 PMC: 11118179. DOI: 10.3390/biom14050573.


Screening data from 19 patients with late-onset Pompe disease for a phase I clinical trial of AAV8 vector-mediated gene therapy.

Hannah W, Case L, Smith E, Walters C, Bali D, Kishnani P JIMD Rep. 2023; 64(5):393-400.

PMID: 37701327 PMC: 10494494. DOI: 10.1002/jmd2.12391.